Author of 1 Presentation
SS 14.8 - Cryoablation for abdominal tumoral implants: a case series
Abstract
Purpose
Percutaneous cryoablation (CA) is widely used for the treatment of primary cancers and metastases with excellent outcomes. Results of CA for abdominal tumoral implants are limited. The purpose of this report is to show our preliminary results of CA of abdominal implants.
Material and methods
A retrospective analysis was performed of metastatic patients treated by means of CA for an abdominal tumoral implant between November 2018 and October 2019. All patients were discussed in a multidisciplinary tumour board. Complete ablation was defined as no local tumour enhancement on the first follow-up imaging. Adverse events (AE) were registered according to the SIR classification.
Results
Eight patients received CA for an abdominal tumoral implant of their renal cancer (n=3), colorectal cancer (n=2), endometrial cancer (n=2), granulosa cell cancer (n=1) and lung cancer (n=1). Abdominal implants were located retroperitoneally (n=4), in the abdominal wall (n=2), pancreas (n=1) and anterior of the stomach (n=1). Median size of the implants was 1.7 cm (R 1.1-3.7cm). Complete ablation was achieved in all lesions. One patient developed an AE grade 2 consisting of psoas muscle pain that was successfully treated with medication.
Conclusion
Cryoablation in the abdomen can be safely and effectively used for tumour control in an oligometastatic setting.
Video-on-demand
Author of 1 Presentation
SS 14.8 - Cryoablation for abdominal tumoral implants: a case series (ID 1070)
Abstract
Purpose
Percutaneous cryoablation (CA) is widely used for the treatment of primary cancers and metastases with excellent outcomes. Results of CA for abdominal tumoral implants are limited. The purpose of this report is to show our preliminary results of CA of abdominal implants.
Material and methods
A retrospective analysis was performed of metastatic patients treated by means of CA for an abdominal tumoral implant between November 2018 and October 2019. All patients were discussed in a multidisciplinary tumour board. Complete ablation was defined as no local tumour enhancement on the first follow-up imaging. Adverse events (AE) were registered according to the SIR classification.
Results
Eight patients received CA for an abdominal tumoral implant of their renal cancer (n=3), colorectal cancer (n=2), endometrial cancer (n=2), granulosa cell cancer (n=1) and lung cancer (n=1). Abdominal implants were located retroperitoneally (n=4), in the abdominal wall (n=2), pancreas (n=1) and anterior of the stomach (n=1). Median size of the implants was 1.7 cm (R 1.1-3.7cm). Complete ablation was achieved in all lesions. One patient developed an AE grade 2 consisting of psoas muscle pain that was successfully treated with medication.
Conclusion
Cryoablation in the abdomen can be safely and effectively used for tumour control in an oligometastatic setting.